

27 Sep 2020 |

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by *Scrip*.

Take a brief audio tour around *Scrip's* Five Must-Know Things, this time covering key developments reported in the business week ended 25 September 2020.

Significant new data from ESMO, Pfizer's changing oncology strategy, and a critical drug pricing hearing in the US are among the items on the agenda in this episode.

This and other Informa Pharma Intelligence podcasts are also now voice-accessible as a skill on Alexa smart speakers and the Alexa app, under the "Business and Finance" category. Just say "Alexa, Open Informa - Pharma Intelligence" and you can then ask for a specific podcast.

Stories mentioned in this episode:

(Also see "[ESMO: A Tale Of Two CDK 4/6 Inhibitors With monarchE Success and Failure For PALLAS](#)" - Scrip, 21 Sep, 2020.)

(Also see "[ESMO: Pfizer's Lorbrena Makes Case To Claim ALK+ Lung Cancer CROWN](#)" - Scrip, 20 Sep, 2020.)

(Also see "[Amgen's KRAS Inhibitor Shows Durability; Pivotal Data Possible This Year](#)" - Scrip, 21 Sep, 2020.)

(Also see "[Pfizer Oncology Pipeline Shows Pivot To Targeted Therapies](#)" - Scrip, 22 Sep, 2020.)

(Also see "[Why Is Congress Targeting These Six Medicines In Drug Price Hearing?](#)" - Scrip, 23 Sep, 2020.)

[Click here to explore this interactive content online](#) 